Date: 2014-11-13
Type of information: Development agreement
Compound: AN363
Company: Saniona (Denmark) Syngene (India)
Therapeutic area: CNS diseases
Type agreement:
Action mechanism:
Disease: neuropathic pain
Details: * On November 13, 2014, Saniona, a leading biotech company within ion-channel research, announced that it has entered into an agreement with Syngene, India, for development of the pre-clinical package for its GABA compound, AN363, which is under development for neuropathic pain. The preclinical development package comprises upscaling of the manufacturing process, GMP production and various safety studies, which
combined form the basis for regulatory approval to begin clinical trials (first in man-studies).
The agreement includes an element of risk sharing, which means that a significant part of the standard pre-clinical package first will be payable upon successful initiation of phase 1 clinical trial. Saniona and Syngene will initiate the program immediately with the objective of initiating phase 1 clinical
trials for AN363 during the first quarter of 2016.
Financial terms:
Latest news:
